Our Leadership

  • John Lewicki, Ph. D.
    President and CEO
    Dr. Lewicki has been OncoMed's President and CEO since March 2018 after having been named the company's President in January 2018. Dr. Lewicki joined OncoMed in 2004 as the company's Senior Vice President of Research and Development before subsequently assuming additional leadership roles within Research and Development. He was named the company's Executive Vice President and Chief Scientific Officer in 2009 and then became Executive Vice President, Research and Development in 2016.

    Earlier in his career, Dr. Lewicki served in various capacities at Scios, Inc., where as Vice President of Research, he managed the company's organization across diverse therapeutic areas. Among his achievements while at Scios was the co-discovery of human B-type natriuretic peptide (BNP). Dr. Lewicki subsequently contributed to Scios' development of BNP into an FDA-approved treatment (Natrecor) for acute congestive heart failure (CHF) and supported licensing partners in the development of an approved clinical test measuring plasma BNP to aid in the differential diagnosis of CHF.

    Dr. Lewicki received his PhD from the University of California, San Diego, and did his postdoctoral studies in the laboratory of Dr. Ferid Murad at the University of Virginia and Stanford University. He has co-authored over 80 original papers and book chapters and is a co-inventor on over 30 issued US patents.
  • Austin Gurney Ph. D.
    Chief Scientific Officer
    Senior Vice President, Research
    Austin Gurney serves as OncoMed's Chief Scientific Officer and Senior Vice President, Research. Dr Gurney joined OncoMed Pharmaceuticals at its founding as Vice President of Molecular and Cellular Biology. Prior to OncoMed, Dr. Gurney worked at Genentech where his research contributed to the discovery of numerous growth factors and cytokines. He has authored or co-authored more than 60 papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer. Dr. Gurney has two decades of experience in biotechnology and in the development of novel therapeutics.

    Dr. Gurney conducted his Ph.D. work at Case Western Reserve University. He completed post doctoral studies with Dr. Bryan Williams at the Cleveland Clinic, and at Genentech with Dr. David Goeddel.
  • Alicia J. Hager, J.D., Ph.D.
    Senior Vice President and General Counsel
    Dr. Hager is Senior Vice President and General Counsel of OncoMed Pharmaceuticals. Prior to her appointment as General Counsel, Dr. Hager served as OncoMed’s Vice President, Legal Affairs and Chief Patent Counsel. Dr. Hager joined OncoMed in 2008 from the international law firm of Morrison & Foerster LLP, where she served as IP counsel for a number of biotech and pharmaceutical clients. Earlier in her career, Dr. Hager was a patent agent at the law firm of Heller Ehrman White & McAuliffe LLP. Dr. Hager received her J.D. from Stanford Law School, with distinction, and her Ph.D. and A.M. in Chemistry from Harvard University. She received her A.B. in Chemistry from Occidental College.
  • Robert Stagg, Pharm. D.
    Senior Vice President, Clinical Research and Development
    Dr. Stagg is a Pharm.D. with extensive experience in Oncology drug development. Dr. Stagg joined OncoMed from PDL BioPharma where he served as Vice President of Regulatory and Drug Safety and prior to that as Senior Medical Director. Prior to PDL BioPharma, Dr. Stagg had served in a variety of clinical research capacities including Senior Director, Clinical Research for Tularik, Inc., Vice President, Clinical Research for Coulter Pharmaceutical, Director, Clinical Research at Gilead Sciences, Inc. and Medical Monitor at Genentech, Inc.

    Dr. Stagg received his Pharm.D. from the University of the Pacific and he subsequently did his residency and Oncology fellowship at the University of California, San Francisco (UCSF). Subsequently, he joined the faculty at UCSF where he was an Assistant Clinical Professor from July 1983 to January 1991. While at UCSF his primary focus was oncology clinical research.
  • Jill Henrich
    Senior Vice President, Regulatory Affairs and Quality Assurance
    Jill Henrich serves as OncoMed's Senior Vice President of Regulatory Affairs and Quality Assurance, and joined OncoMed as Vice President, Regulatory Affairs in January 2009. She provides oversight over all aspects of global Regulatory Affairs and Quality Assurance strategy, implementation and execution. Prior to joining OncoMed, Ms. Henrich was at PDL BioPharma, Inc., most recently as Executive Director of Regulatory Affairs and Quality Assurance providing strategic management and oversight for all regulatory interactions, Regulatory Operations/Corporate Document Control, Medical Writing and QA/Compliance activities. Prior to joining PDL BioPharma, Inc., Ms. Henrich was the Senior Director of Regulatory Affairs at Corixa Corporation (formerly Coulter Pharmaceutical, Inc.), and held various positions in Research (Cell Genetics/Molecular Biology) and Regulatory Affairs at Genentech, Inc. from 1987 through 1997, where she maintained global regulatory responsibility for two approved marketed products and multiple products in various phases of development. Ms. Henrich received her Bachelor of Science degree in Biological Sciences/Microbiology from the University of Connecticut.
  • Ann Kapoun
    Senior Vice President, Translational Medicine
    Ann Kapoun, Ph.D., serves as Sr. Vice President of Translational Medicine. She brings to OncoMed more than two decades of leadership and experience in translational sciences and biomarkers, particularly in the areas of oncology and early clinical development. Dr. Kapoun oversees broad functions in preclinical and translational drug development and is responsible for the clinical execution and implementation of biomarkers and companion diagnostics. Prior to joining OncoMed, Dr. Kapoun established and built highly effective translational departments from inception at ALZA / Johnson & Johnson, where she was as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine, and at Scios Inc. where she created and led their Biomarker and Pharmacogenomics programs in support of multiple phase 1-3 clinical trials. Dr. Kapoun received her Ph.D. from Indiana University, Bloomington, IN, and she has coauthored more than 50 scientific publications and patents.
  • Yvonne Li
    Vice President of Finance, Controller and Administration
    Yvonne Li has served as Vice President of Finance, Controller and Administration since 2014 and has actively managed the Accounting and Finance department at OncoMed as Controller since 2007. Ms. Li has played key roles in the company's initial public offering, three major collaborations with GSK, Bayer and Celgene, private equity financing, strategic business plan and risk management. In addition, Ms. Li manages the company's purchasing, HR and IT groups. Prior to joining OncoMed, she served as Director of Accounting at Anita Borg Institute and held various positions at Actel Corporation. Ms. Li has also worked in the Internal Audit Department at Stanford University. Ms. Li received a Master of Business Administration in Finance from San Francisco State University. Ms. Li is a member of the American Institute of Certified Public Accountants.
  • Leonardo Faoro, MD, MBA
    Vice President, Clinical Development
    Dr. Faoro is a medical oncologist with extensive pharmaceutical oncology drug development experience. He joined OncoMed from Genentech, a member of the Roche Group, where he was the Global Clinical Leader for Avastin ® (bevacizumab) for metastatic breast cancer indications. While at Genentech, Dr. Faoro also worked on Avastin in other indications, including non-small cell lung cancer, renal cell carcinoma, prostate cancer, and cervical cancer. In this role, he led the clinical development activities for Avastin in these indications.

    Dr. Faoro received his medical degree from the Universidade Federal do Parana, Brazil, and subsequently completed medical residency in Internal Medicine at the Mayo Clinic followed by a fellowship in Medical Oncology at the University of Chicago. While in Chicago, Dr. Faoro worked in Dr. Ravi Salgia's lab, focusing on signaling inhibitors, with targets such as protein kinase C, PARP, and c-Met, while continuing his clinical activities in the area of thoracic oncology. Dr. Faoro also earned an MBA from the University of California, Berkeley, as well as from Columbia University.

Our Partners